Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBT Margin: 2020-2025

Historic EBT Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to 47.17%.

  • Apellis Pharmaceuticals' EBT Margin rose 7606.00% to 47.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.59%, marking a year-over-year increase of 3924.00%. This contributed to the annual value of -25.18% for FY2024, which is 10758.00% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' EBT Margin stood at 47.17%, which was up 301.99% from -23.35% recorded in Q2 2025.
  • Apellis Pharmaceuticals' EBT Margin's 5-year high stood at 4,399.02% during Q1 2021, with a 5-year trough of -35,183.15% in Q2 2021.
  • In the last 3 years, Apellis Pharmaceuticals' EBT Margin had a median value of -38.45% in 2024 and averaged -76.80%.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' EBT Margin slumped by 3,694,016bps in 2021, and later surged by 3,423,050bps in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' EBT Margin (Quarterly) stood at -244.79% in 2021, then slumped by 49,414bps to -738.92% in 2022, then spiked by 67,938bps to -59.54% in 2023, then skyrocketed by 4,257bps to -16.97% in 2024, then skyrocketed by 7,606bps to 47.17% in 2025.
  • Its EBT Margin was 47.17% in Q3 2025, compared to -23.35% in Q2 2025 and -55.09% in Q1 2025.